PPAR Agonists and Cardiovascular Disease in Diabetes
2008

PPAR Agonists and Cardiovascular Disease in Diabetes

publication Evidence: moderate

Author Information

Author(s): Anna C. Calkin, Merlin C. Thomas

Primary Institution: JDRF Center for Diabetes Complications, Baker Heart Research Institute, Melbourne, VIC, Australia

Hypothesis

Do PPAR agonists reduce cardiovascular risk in patients with diabetes?

Conclusion

PPAR agonists have independent anti-atherosclerotic actions, but their clinical benefits in reducing cardiovascular events in diabetes remain uncertain.

Supporting Evidence

  • PPAR agonists can improve lipid profiles and insulin sensitivity in patients with diabetes.
  • Clinical trials show mixed results regarding the cardiovascular benefits of PPAR agonists.
  • Some PPAR agonists have been associated with increased cardiovascular events.

Takeaway

PPAR agonists are medications that help manage diabetes and may also protect the heart, but they can sometimes cause problems like fluid retention.

Methodology

The review examines the effects of PPAR agonists on cardiovascular disease in diabetes, discussing their mechanisms and clinical trial outcomes.

Limitations

The clinical efficacy of PPAR agonists is controversial, with mixed results in trials regarding their cardiovascular benefits.

Digital Object Identifier (DOI)

10.1155/2008/245410

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication